158 related articles for article (PubMed ID: 33373380)
1. Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study.
Muwonge R; Basu P; Gheit T; Anantharaman D; Verma Y; Bhatla N; Joshi S; Esmy PO; Poli URR; Shah A; Zomawia E; Shastri SS; Pimple S; Prabhu PR; Hingmire S; Chiwate A; Sauvaget C; Lucas E; Malvi SG; Siddiqi M; Sankaran S; Kannan TPRA; Varghese R; Divate U; Vashist S; Mishra G; Jadhav R; Tommasino M; Pillai MR; Sankaranarayanan R; Jayant K;
PLoS One; 2020; 15(12):e0244242. PubMed ID: 33373380
[TBL] [Abstract][Full Text] [Related]
2. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).
Guo F; Hirth JM; Berenson AB
Hum Vaccin Immunother; 2015; 11(10):2337-44. PubMed ID: 26376014
[TBL] [Abstract][Full Text] [Related]
4. HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: Results from the baseline phase of the Onclarity trial.
Wright TC; Parvu V; Stoler MH; Kodsi S; Eckert K; Yanson K; Cooper CK
Gynecol Oncol; 2019 May; 153(2):259-265. PubMed ID: 30853359
[TBL] [Abstract][Full Text] [Related]
5. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction.
Chandler E; Ding L; Gorbach P; Franco EL; Brown DA; Widdice LE; Bernstein DI; Kahn JA
J Adolesc Health; 2018 Jul; 63(1):43-49. PubMed ID: 30060856
[TBL] [Abstract][Full Text] [Related]
7. Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction.
Ding L; Widdice LE; Kahn JA
Vaccine; 2017 Dec; 35(52):7217-7221. PubMed ID: 29169890
[TBL] [Abstract][Full Text] [Related]
8. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.
Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I;
J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911
[TBL] [Abstract][Full Text] [Related]
11. Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women.
El-Zein M; Ramanakumar AV; Naud P; Roteli-Martins CM; de Carvalho NS; Colares de Borba P; Teixeira JC; Moscicki AB; Harper DM; Tyring SK; Ramjattan B; Dubin G; Franco EL;
Sex Transm Dis; 2019 Oct; 46(10):663-669. PubMed ID: 31464859
[TBL] [Abstract][Full Text] [Related]
12. Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine.
Schlecht NF; Masika M; Diaz A; Nucci-Sack A; Salandy A; Pickering S; Strickler HD; Shankar V; Burk RD
JAMA Netw Open; 2019 Oct; 2(10):e1914031. PubMed ID: 31651968
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination.
Mollers M; Scherpenisse M; van der Klis FR; King AJ; van Rossum TG; van Logchem EM; Feltkamp MC; Meijer CJ; Snijders PJ; Boot HJ; de Melker HE
Cancer Epidemiol; 2012 Dec; 36(6):519-24. PubMed ID: 22906483
[TBL] [Abstract][Full Text] [Related]
14. Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany: a long-term prospective, cohort data analysis.
Denecke A; Iftner T; Iftner A; Riedle S; Ocak M; Luyten A; Üye I; Tunc K; Petry KU
BMC Infect Dis; 2021 Jul; 21(1):634. PubMed ID: 34215215
[TBL] [Abstract][Full Text] [Related]
15. Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008-2018, and perspectives on cancer prevention.
Du J; Ährlund-Richter A; Näsman A; Dalianis T
Arch Gynecol Obstet; 2021 Feb; 303(2):329-335. PubMed ID: 33247317
[TBL] [Abstract][Full Text] [Related]
16. Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection.
Saccucci M; Franco EL; Ding L; Bernstein DI; Brown D; Kahn JA
Sex Transm Dis; 2018 Apr; 45(4):260-265. PubMed ID: 29465705
[TBL] [Abstract][Full Text] [Related]
17. Pre-vaccination prevalence of high-risk human papillomaviruses (HPV) in women from Kosovo and their related sociodemographic characteristics.
Zejnullahu Raçi P; Hošnjak L; Poljak M; Lepej SŽ; Vince A
Ginekol Pol; 2018; 89(9):485-494. PubMed ID: 30318575
[TBL] [Abstract][Full Text] [Related]
18. Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial.
Ramanakumar AV; Naud P; Roteli-Martins CM; de Carvalho NS; de Borba PC; Teixeira JC; Blatter M; Moscicki AB; Harper DM; Romanowski B; Tyring SK; Ramjattan B; Schuind A; Dubin G; Franco EL;
BMJ Open; 2016 Aug; 6(8):e011371. PubMed ID: 27566633
[TBL] [Abstract][Full Text] [Related]
19. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.
Basu P; Malvi SG; Joshi S; Bhatla N; Muwonge R; Lucas E; Verma Y; Esmy PO; Poli URR; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Prabhu PR; Kannan TPRA; Varghese R; Shastri SS; Anantharaman D; Gheit T; Tommasino M; Sauvaget C; Pillai MR; Sankaranarayanan R
Lancet Oncol; 2021 Nov; 22(11):1518-1529. PubMed ID: 34634254
[TBL] [Abstract][Full Text] [Related]
20. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018.
Rosenblum HG; Lewis RM; Gargano JW; Querec TD; Unger ER; Markowitz LE
MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(12):415-420. PubMed ID: 33764964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
